Pfizer - Recruiting 18 years or older. - A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events.
Amgen - Recruiting 18 years to 80 years. - A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects.
Part A, Atorvastatin; Part A, Placebo (administered orally); Part B, Evolocumab; Part B, Placebo (administered orally); Part B, Ezetimibe; Part B, Placebo (administered subcutaneously); Part C, Evolocumab
HanAll BioPharma Co., Ltd. - Recruiting 18 years to 80 years. - A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia.
Ohio State University - Recruiting 18 years or older. - An Observational Study Investigating Genetic Influences on Statin Plasma Concentrations in Adults Taking Atorvastatin, Simvastatin, or Lovastatin.
JW Pharmaceutical - Recruiting 20 years to 70 years. - Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4).
Kuhnil Pharmaceutical Co., Ltd. - Recruiting 20 years to 80 years. - A Randomized. Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Combination Therapy of Omega-3-acids Ethylesters 90/Atorvastatin Calcium in Type ?b Hyperlipidemia.
Amgen - Recruiting 20 years to 85 years. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia.
Yuhan Corporation - Recruiting 19 years or older. - A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia.
Chong Kun Dang Pharmaceutical - Recruiting 19 years or older. - Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient: Multi Center, Randomized, Double-blind, Parallel-group, Therapeutic Confirmatory Study..